Eva Meluzínová

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Ludwig Kappos, Ralf Gold, David H. Miller et al. · The Lancet · 2008 · 477 citations · Full text

Relapsing-remitting Multiple Sclerosis, Medicine, Clinical Neurology +6

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch et al. · The Lancet Neurology · 2021 · 177 citations · Full text

Neurological Disorder, Phase 2B, Clinical Trials +7

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 173 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +5

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky et al. · The Lancet Neurology · 2020 · 99 citations · Full text